Actual cases may be as much as 6 to 24 times higher than reported, but we’re still a long way off from herd immunity.

The FDA cracks down on test makers as independent evaluations of their products’ performance show a need for improvement.

Preprints from the first round of seroprevalence studies indicate that many more people have been infected with the virus than previously reported. Some of these studies also have serious design flaws.

Studies from serum samples could transform our understanding of the spread of COVID-19, but what antibodies alone say about immunity is not yet clear.

The virus’s tool for prying open host cells is coated in a protective armor of sugar—but gaps may offer vulnerability to disruption by antibodies.

My lab has developed a protocol to easily assess the specificity of antibodies—and hopefully stem some of the reproducibility crisis.

Executives at a biotech that develops new antibodies argue that Ram Sasisekharan didn’t come up with the structures for at least two experimental therapies that his group has described.

Animal and cell culture studies show evidence that dengue antibodies can both neutralize and enhance Zika, but human investigations have only found protective effects.

Collagen tunnels through mouse lymph nodes ferry antibodies into the bloodstream.